Objectives: Data on liver and non-liver co-morbidities in chronic hepatitis B (CHB) patients are limited. This study analyzes the prevalence of co-morbidities in a multicenter CHB cohort evaluated over 15 years. Methods: This study included 2734 consecutive adult American CHB patients from a university medical center and several community primary care clinics. Data were analyzed by time periods (patients in each time period were unique without overlapping): 2000–2005 (n = 885), 2006–2010 (n = 888), and 2011–2015 (n = 961). Patients were identiﬁed via electronic query using diagnosis code with data conﬁrmed and extracted via individual chart review. Most patients were male (57.9%) and Asian (89.6%). Results: Mean age increased signiﬁcantly from 43.3 ± 13.4 years during 2000–2005 to 49.1 ± 14.4 during 2011–2015 (p < 0.001). Between 2000–2005 and 2011–2015, fatty liver disease among new CHB patients increased from 1.6 to 6.8% (p < 0.001). Advanced liver diseases also increased (p < 0.001): cirrhosis (12.6–24.6%), hepatic decompensation (1.1–7.9%), and hepatocellular carcinoma (HCC) (4.9–9.1%). Similar trends were observed for non-liver co-morbidities (p < 0.001). Speciﬁcally, diabetes increased almost ﬁvefold (4.9–22.9%), hypertension increased threefold (12.3–36.1%) and chronic kidney disease increased 4.5-fold (4.4–19.7%). Prevalence of osteopenia and osteoporosis also increased in
Clinical and Translational Gastroenterology – Springer Journals
Published: Mar 14, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera